DGIdb - RASAGILINE Drug Record

RASAGILINE chembl:CHEMBL887 Approved

Alternate Names:

TV-1030
AGN-1135
RASAGILINE
AZILECT
(1R)-N-PROPARGYLINDAN-1-AMINE
(R)-INDAN-1-YL-PROP-2-YNYL-AMINE
(R)-N-2-PROPYNYL-1-INDANAMINE
RAS
TVP-1012
AZILECT®
chembl:CHEMBL887
chemidplus:136236-51-6
rxcui:134748
pubchem.compound:3052776
drugbank:01367

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antiparkinson agent
Drug Class	antiparkinson agents
Year of Approval	2006

(1 More Sources)

Publications:

Chau et al., 2010, Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells., Neurochem. Int.
Uzun et al., Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits., Eur Rev Med Pharmacol Sci
Weinreb et al., 2010, Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity., Prog. Neurobiol.
Chen et al., 2007, Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease., Clin Ther
Youdim et al., Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition., J. Neurosci. Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Naoi et al., 2009, Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease., Expert Rev Neurother
Leegwater-Kim et al., 2010, The role of rasagiline in the treatment of Parkinson's disease., Clin Interv Aging
Youdim et al., 2001, Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]., Cell. Mol. Neurobiol.
Masellis M et al., 2016, Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study., Brain

RASAGILINE MAOB

Interaction Score: 8.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name rasagiline mesylate, TVP-1012,Agilect

Novel drug target Established target

PMIDs:
20624440 19499843 20600573 18035186 15573406 11752352 19673610 20517484 12043833

Sources:
TdgClinicalTrial TEND TTD
RASAGILINE DRD2

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27190009

Sources:
PharmGKB

TEND: RASAGILINE
- Version: 01-August-2011
Alternate Names:

RASAGILINE Primary Drug Name

Drug Info:

Year of Approval 2006

Drug Class antiparkinson agents

Publications:
TdgClinicalTrial: RASAGILINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiparkinson agent

Drug Class Small Molecule

FDA Approval approved

Publications:
PharmGKB: rasagiline
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Masellis M et al., 2016, Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study., Brain
TTD: Rasagiline
- Version: 2020.06.01
Alternate Names:

D06OMW TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL887
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	rasagiline mesylate, TVP-1012,Agilect
Novel drug target	Established target

RASAGILINE Drug Record

RASAGILINE chembl:CHEMBL887 Approved

Alternate Names:

Drug Info:

Publications:

RASAGILINE MAOB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name rasagiline mesylate, TVP-1012,Agilect Novel drug target Established target

PMIDs: 20624440 19499843 20600573 18035186 15573406 11752352 19673610 20517484 12043833

Sources: TdgClinicalTrial TEND TTD

RASAGILINE DRD2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27190009

Sources: PharmGKB

TEND: RASAGILINE

Alternate Names: RASAGILINE Primary Drug Name

Drug Info: Year of Approval 2006 Drug Class antiparkinson agents

Publications:

TdgClinicalTrial: RASAGILINE

Alternate Names:

Drug Info: Drug Indications antiparkinson agent Drug Class Small Molecule FDA Approval approved

Publications:

PharmGKB: rasagiline

Alternate Names:

Drug Info:

Publications: Masellis M et al., 2016, Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study., Brain

TTD: Rasagiline

Alternate Names: D06OMW TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL887

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name rasagiline mesylate, TVP-1012,Agilect

Novel drug target Established target

PMIDs:
20624440 19499843 20600573 18035186 15573406 11752352 19673610 20517484 12043833

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
27190009

Sources:
PharmGKB

Alternate Names:

RASAGILINE Primary Drug Name

Drug Info:

Year of Approval 2006

Drug Class antiparkinson agents

Drug Info:

Drug Indications antiparkinson agent

Drug Class Small Molecule

FDA Approval approved

Publications:

Masellis M et al., 2016, Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study., Brain

Alternate Names:

D06OMW TTD Drug ID